Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Collapse authors list.
Khanna, D, Denton, CP, Jahreis, A, van Laar, JM, Frech, TM, Anderson, ME, Baron, M, Chung, L, Fierlbeck, G, Lakshminarayanan, S et al (show 14 more authors) , Allanore, Y, Pope, JE, Riemekasten, G, Steen, V, Mueller-Ladner, U, Lafyatis, R, Stifano, G, Spotswood, H, Chen-Harris, H, Dziadek, S, Morimoto, A, Sornasse, T, Siegel, J and Furst, DE (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. The Lancet, 387 (10038). 2630 - 2640.

Text 101101617 SSc Ms rev FINAL Tracked.docx - Accepted Version Download (7MB)

Item Type:	Article
Depositing User:	Symplectic Admin
Date Deposited:	25 Jan 2019 11:31
Last Modified:	23 Jan 2022 07:10
DOI:	10.1016/S0140-6736(16)00232-4
Related URLs:	Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3030738

Available Versions of this Item

• Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. (deposited 11 May 2016 09:19)
  • Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. (deposited 25 Jan 2019 11:31) [Currently Displayed]